NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
Press Release
Read More
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
Press Release
Read More
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
Press Release
Read More
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting
Press Release
Read More